3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Triple Negative Breast Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
Cyclophosphamide
135
aldesleukin
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
68
dabrafenib
65
fludarabine phosphate
62
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
Magnetic Resonance Spectroscopy
33
cobimetinib
32
Specimen Handling
31
Introns
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled